- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOVIE Aktie jetzt für 0€ handeln | |||||
| 20.10. | BioVie reports positive bezisterim trial results in Parkinson's | 1 | Investing.com | ||
| 20.10. | BioVie meldet positive Phase-2-Ergebnisse für Bezisterim bei Parkinson | 10 | Investing.com Deutsch | ||
| 26.09. | New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global | 754 | ACCESS Newswire | Gold-backed payments, enterprise AI, a Long COVID clinical readout and AI-powered school safety lead a 6:30 p.m. ET broadcast reaching audiences across the United States, Latin America and MENA NEW... ► Artikel lesen | |
| 19.09. | New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global | 1.029 | ACCESS Newswire | BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient Needs NEW YORK CITY, NY / ACCESS Newswire... ► Artikel lesen | |
| 18.09. | RedChip Companies, Inc.: Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV | 585 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / September 18, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and BioVie Inc. (Nasdaq:BIVI) on the RedChip Small... ► Artikel lesen | |
| 16.09. | RedChip Companies, Inc.: Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results | 462 | ACCESS Newswire | BioVie CEO Cuong Do to discuss newly reported Phase 2 data showing bezisterim's potential across key Long COVID symptomsLearn why the ADDRESS-LC findings, together with recent Parkinson's data, could... ► Artikel lesen | |
| 15.09. | What's Going On With BioVie Stock on Tuesday? | 3 | Benzinga.com | ||
| 15.09. | Studienfehlschlag bei Long COVID: BioVie Aktie bricht ein | 30 | Investing.com Deutsch | ||
| 15.09. | BioVie reports phase 2 long COVID trial results | 2 | Investing.com | ||
| 15.09. | BioVie, Inc.: BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID | 668 | GlobeNewswire (Europe) | Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post-exertional malaise Bezisterim... ► Artikel lesen | |
| 08.09. | BioVie, Inc.: BioVie Announces Update to Parkinson's Phase 3 Development Program | 462 | GlobeNewswire (Europe) | CARSON CITY, Nev., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative... ► Artikel lesen | |
| 31.08. | BioVie, Inc.: BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID | 338 | GlobeNewswire (Europe) | CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative... ► Artikel lesen | |
| 14.08. | BIOVIE INC. - S-1/A, General form for registration of securities | 7 | SEC Filings | ||
| 14.08. | RedChip Companies, Inc.: First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV | 567 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / August 14, 2026 / RedChip Companies will air interviews with First Phosphate Corp. (NASDAQ:PHOS)(CSE:PHOS)(OTCQX:FRSPF)(FSE:KD0) and BioVie Inc. (Nasdaq:BIVI) on the... ► Artikel lesen | |
| 08.08. | New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results | 2.074 | ACCESS Newswire | Sponsored Programming Also Broadcasts Across Bloomberg Television in Latin America and MENA, Expanding the Global Reach of New to The Street's Featured Companies NEW YORK CITY, NY / ACCESS Newswire... ► Artikel lesen | |
| 07.08. | RedChip Companies, Inc.: Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results | 1.095 | ACCESS Newswire | BioVie CEO Cuong Do to discuss the newly released Phase 2 SUNRISE-PD results and what they mean for the future development of bezisterim in Parkinson's diseaseLearn how the BioVie's differentiated approach... ► Artikel lesen | |
| 06.08. | BioVie's stock sinks 50% as company uses composite endpoint to make case for Parkinson's program | 9 | FierceBiotech | ||
| 06.08. | BioVie reports positive phase 2 trial results for Parkinson's drug | 5 | Investing.com | ||
| 06.08. | BioVie meldet positive Phase-2-Studienergebnisse für Parkinson-Medikament | 5 | Investing.com Deutsch | ||
| 06.08. | BioVie, Inc.: BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease | 1.003 | GlobeNewswire (Europe) | Patients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS1 Parts I, II, and III, as well... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,50 | +0,45 % | BioNTech, Formycon, Biogen - Pharma-Milliarden werden neu verteilt | Die Pharmaindustrie steht vor einer gewaltigen Neuordnung. Während milliardenschwere Blockbuster-Medikamente ihre Patentexklusivität verlieren, drängen günstigere Nachahmer-Präparate auf den Markt.... ► Artikel lesen | |
| EVOTEC | 2,924 | +1,67 % | Evotec-Aktie mit +15% - steht die Trendwende jetzt an? | Die Evotec-Aktie meldet sich mit einem Wochenplus von +6,08% zurück und notiert bei 2,72 €. Von einer nachhaltigen Erholung kann dennoch keine Rede sein: Seit dem Rekordhoch hat der Biotech-Titel fast... ► Artikel lesen | |
| MEDIGENE | 0,004 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| AMGEN | 399,05 | -0,91 % | Amgen declares $2.52 dividend | ||
| NOVAVAX | 8,950 | -0,33 % | Novavax: Großaktionär zieht sich zurück - was nun? | ||
| STRYKER | 270,00 | -0,26 % | Stryker Completes ZuriMED Deal, Adds FiberLocker System To Sports Medicine Portfolio | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK), a medical technology company, on Monday announced the completion of its acquisition of ZuriMED, a privately held company that developed the FiberLocker... ► Artikel lesen | |
| BIOGEN | 224,60 | -1,04 % | Biogen Slips To Loss In Q3; Raises Low-end Of FY26 Earnings View | WESTON (dpa-AFX) - Biotech major Biogen Inc. (BIIB) reported Wednesday a loss in its third quarter, compared to prior year's profit, despite higher revenues. Further, the firm raised the lower... ► Artikel lesen | |
| AAP IMPLANTATE | 1,430 | -2,72 % | aap Implantate: Cornelius Fink und Nicole Kassel neu im Vorstand | Bei aap Implantate kommt es zu Veränderungen im Vorstand. CEO Rubino Di Girolamo wird sein Amt zum 31. Dezember 2026 im Einvernehmen mit dem Aufsichtsrat niederlegen und vorzeitig aus dem Vorstand ausscheiden.... ► Artikel lesen | |
| CLINUVEL | 4,483 | -0,64 % | Dividendenbekanntmachungen (03.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADMIRAL GROUP PLC GB00B02J6398 0,705 GBP 0,8204 EUR AEGON LTD ADR US0076CA1045 0,2455 USD 0,2118 EUR AMCOR PLC CDIS AU000000AMC4 0... ► Artikel lesen | |
| VIKING THERAPEUTICS | 21,950 | -2,23 % | NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains? | ||
| INTELLIA THERAPEUTICS | 10,860 | -0,91 % | Intellia Therapeutics-Aktie: Sind 80 US$ möglich? | Die Intellia-Therapeutics-Aktie notiert aktuell bei 12,37 US$ und damit mehr als -90% unter ihrem bisherigen Rekordhoch. Nach dem Ausbruch aus dem langjährigen Abwärtstrend versucht der Biotech-Titel... ► Artikel lesen | |
| TEMPUS AI | 66,96 | +3,86 % | Tempus AI, Inc.: Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling | Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certification under the European Union's In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device.... ► Artikel lesen | |
| NOVONESIS | 62,10 | -1,24 % | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | ||
| COSCIENS BIOPHARMA | 5,330 | +2,30 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,229 | -4,58 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen |
Das Unternehmen BIOVIE INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVIE INC finden Sie auf Wallstreet Online.